Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

153.85 -3.36 (-2.14%)
Streaming Delayed Price Updated: 3:34 PM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 853,784
Open 156.59
Bid (Size) 153.76 (200)
Ask (Size) 153.97 (100)
Prev. Close 157.21
Today's Range 153.27 - 156.88
52wk Range 117.59 - 162.39
Shares Outstanding 100,100,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Value Gem With Solid Fundamentals ↗
Via Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a Peter Lynch-Style GARP Opportunity ↗
Via Chartmill

Performance

YTD
+9.4%
+9.4%
1 Month
+16.9%
+16.9%
3 Month
+20.4%
+20.4%
6 Month
+7.2%
+7.2%
1 Year
+25.3%
+25.3%

More News

Read More
News headline image
Neurocrine (NBIX) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Neurocrine Biosciences (NASDAQ:NBIX) Smashes Q1 Estimates with 44% Sales Surge ↗
Via Chartmill
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
From Brodsky & Smith LLC
Via GlobeNewswire
Neurocrine Biosciences Inc (NASDAQ:NBIX) Qualifies for Affordable Growth Screen with Strong GARP Profile ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with a Bullish Technical Setup ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top Affordable Growth Stock ↗
Via Chartmill
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avanos Medical, Inc. (NYSE – AVNS), Leggett & Platt, Incorporated (NYSE – LEG), Soleno Therapeutics, Inc. (Nasdaq – SLNO), Forian, Inc. (Nasdaq – FORA)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
Via MarketMinute
Neurocrine Biosciences Inc. (NASDAQ:NBIX) Presents a Strong Growth and Technical Setup ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Case as a Quality Value Stock ↗
Via Chartmill
News headline image
Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
Via Finterra
Topics Economy Intellectual Property
Wall Street Holds Its Ground While Trump's Iran Deadline Ticks Down ↗
Via Chartmill
Topics Government
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top GARP Pick with Strong Growth and a Reasonable Price ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Fundamentals and a Bullish Chart Pattern ↗
Via Chartmill
News headline image
Why Soleno Therapeutics Stock Rocketed Higher on Monday ↗
Via The Motley Fool
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Soleno Therapeutics, Inc. (Nasdaq – SLNO), Affinity Bancshares, Forian, Inc. (Nasdaq – FORA), Janus Henderson Group plc (NYSE - JHG)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
Via MarketMinute
Topics Intellectual Property
News headline image
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead ↗
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Neurocrine Biosciences, Inc. - Common Stock publicly traded?
Yes, Neurocrine Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Neurocrine Biosciences, Inc. - Common Stock trade on?
Neurocrine Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Neurocrine Biosciences, Inc. - Common Stock?
The ticker symbol for Neurocrine Biosciences, Inc. - Common Stock is NBIX on the Nasdaq Stock Market
What is the current price of Neurocrine Biosciences, Inc. - Common Stock?
The current price of Neurocrine Biosciences, Inc. - Common Stock is 153.85
When was Neurocrine Biosciences, Inc. - Common Stock last traded?
The last trade of Neurocrine Biosciences, Inc. - Common Stock was at 05/19/26 03:34 PM ET
What is the market capitalization of Neurocrine Biosciences, Inc. - Common Stock?
The market capitalization of Neurocrine Biosciences, Inc. - Common Stock is 15.40B
How many shares of Neurocrine Biosciences, Inc. - Common Stock are outstanding?
Neurocrine Biosciences, Inc. - Common Stock has 15B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.